Ambrosia Biosciences secured an oversubscribed $100 million Series B to advance its oral obesity drug pipeline, including its lead oral small-molecule GLP-1 candidate. The company plans to move the lead program into Phase 1 trials and expand next-wave metabolic programs targeting additional pathways such as GIP and amylin. The financing adds new investors alongside existing backers, underscoring market appetite for orally administered weight-loss candidates designed for combinability. With GLP-1 injections now well established, Ambrosia is betting that oral small molecules can carve out a distinct label and dosing convenience. For biotech, the funding also reinforces how investors are repositioning toward metabolic franchises with clear oral administration differentiation and scalable chemistry.